Media stories about Stryker (NYSE:SYK) have trended somewhat positive on Sunday, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Stryker earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave media headlines about the medical technology company an impact score of 47.1628681727293 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s analysis:
SYK has been the subject of a number of research reports. Robert W. Baird upgraded Stryker from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $161.00 to $173.00 in a report on Thursday, November 16th. SunTrust Banks reiterated a “buy” rating and issued a $161.00 price target on shares of Stryker in a report on Friday, November 17th. Wells Fargo & Co boosted their price target on Stryker from $160.00 to $166.00 in a report on Friday, October 27th. Barclays boosted their price target on Stryker from $137.00 to $148.00 and gave the company an “underweight” rating in a report on Friday, October 27th. Finally, Leerink Swann boosted their price target on Stryker from $177.00 to $184.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the stock. Stryker currently has an average rating of “Hold” and an average price target of $162.50.
Shares of Stryker (NYSE SYK) traded up $1.33 during trading hours on Friday, reaching $159.87. 1,065,280 shares of the company were exchanged, compared to its average volume of 1,611,725. The company has a market capitalization of $59,894.02, a P/E ratio of 59.65, a price-to-earnings-growth ratio of 2.30 and a beta of 0.70. Stryker has a 52 week low of $124.89 and a 52 week high of $170.00. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66.
Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.95 by $0.01. The business had revenue of $3.47 billion for the quarter, compared to the consensus estimate of $3.42 billion. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The business’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.78 earnings per share. equities analysts anticipate that Stryker will post 7.12 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.18%. The ex-dividend date of this dividend is Wednesday, March 28th. Stryker’s payout ratio is presently 70.15%.
In other news, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $163.76, for a total transaction of $818,800.00. Following the transaction, the insider now directly owns 94,253 shares of the company’s stock, valued at $15,434,871.28. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP William E. Berry, Jr. sold 1,306 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $164.42, for a total value of $214,732.52. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,840 shares of company stock worth $2,749,989. Insiders own 7.40% of the company’s stock.
WARNING: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/18/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-stryker-syk-share-price.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.